# Hyperthyroidism-Induced Dural Venous Sinus Thrombosis: A Case Report

**Authors:** Anas E Ahmed, Abdulrahman K Alghamdi, Yasmin A Alghamdi, Jannat K Aljohani, Ghada G Almaziad

PMC · DOI: 10.7759/cureus.102166 · Cureus · 2026-01-23

## TL;DR

A young woman with hyperthyroidism developed dural venous sinus thrombosis, which improved with anticoagulation and thyroid treatment.

## Contribution

Highlights hyperthyroidism as a reversible cause of cerebral venous sinus thrombosis.

## Key findings

- Thrombosis occurred in a patient with Graves’ disease and no other thrombophilia risk factors.
- Symptoms resolved with anticoagulation and antithyroid therapy.
- Radiological evidence showed sinus recanalization after treatment.

## Abstract

Cerebral dural venous sinus thrombosis is an uncommon and potentially life-threatening cerebrovascular disorder with a broad and often nonspecific clinical spectrum, frequently leading to diagnostic delay. We describe a young woman with no prior comorbidities who presented with a subacute history of progressively worsening headache associated with visual disturbances and pulsatile tinnitus. Neuroimaging with computed tomography and magnetic resonance venography demonstrated acute thrombosis of the right transverse dural venous sinus without parenchymal infarction or hemorrhage. Comprehensive laboratory evaluation revealed overt thyrotoxicosis with positive thyroid autoantibodies consistent with Graves’ disease, while an extensive thrombophilia work-up failed to identify alternative prothrombotic risk factors. The patient was treated with therapeutic anticoagulation alongside prompt initiation of antithyroid therapy and beta-adrenergic blockade, leading to progressive symptom resolution, biochemical improvement toward euthyroidism, and radiological evidence of sinus recanalization on follow-up. This case emphasizes hyperthyroidism as an underrecognized yet reversible cause of cerebral venous sinus thrombosis and highlights the importance of systematic etiological evaluation, including thyroid function assessment, in patients with cerebral venous thrombosis to enable early targeted therapy and favorable neurological outcomes.

## Linked entities

- **Diseases:** hyperthyroidism (MONDO:0004425), Graves’ disease (MONDO:0005364)

## Full-text entities

- **Genes:** FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, SERPINC1 (serpin family C member 1) [NCBI Gene 462] {aka AT3, AT3D, ATIII, ATIII-R2, ATIII-T1, ATIII-T2}, TPO (thyroid peroxidase) [NCBI Gene 7173] {aka MSA, TDH2A, TPX}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, F5 (coagulation factor V) [NCBI Gene 2153] {aka FVL, PCCF, RPRGL1, THPH2, fV}, PROC (protein C, inactivator of coagulation factors Va and VIIIa) [NCBI Gene 5624] {aka APC, PC, PROC1, THPH3, THPH4}, TSHR (thyroid stimulating hormone receptor) [NCBI Gene 7253] {aka CHNG1, LGR3, hTSHR-I}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, F9 (coagulation factor IX) [NCBI Gene 2158] {aka F9 p22, FIX, HEMB, P19, PTC, THPH8}
- **Diseases:** photophobia (MESH:D020795), intracerebral hemorrhage (MESH:D002543), tremor (MESH:D014202), venous thromboembolic (MESH:D054556), blurred vision (MESH:D014786), altered consciousness (MESH:D003244), thrombosis (MESH:D013927), thyrotoxic (MESH:D013958), symptoms (MESH:D012816), inflammation (MESH:D007249), headache (MESH:D006261), trauma (MESH:D014947), papilledema (MESH:D010211), anxiety (MESH:D001007), leukocytosis (MESH:D007964), meningeal irritation (MESH:D008580), weight loss (MESH:D015431), DVT (MESH:D020246), dehydration (MESH:D003681), transverse sinus occlusion (MESH:D020227), neck stiffness (MESH:D006258), endothelial injury (MESH:D057772), cerebrovascular disease (MESH:D002561), endocrine disorder (MESH:D004700), malignancy (MESH:D009369), hemorrhagic venous infarction (MESH:D020520), endothelial dysfunction (MESH:D014652), focal limb weakness (MESH:D018908), infection (MESH:D007239), pulsatile tinnitus (MESH:D014012), Cerebral DVST (MESH:D012851), loss of consciousness (MESH:D014474), lid retraction (MESH:D004370), Hyperthyroidism (MESH:D006980), palpitations (MESH:D006331), strokes (MESH:D020521), thyrotoxicosis (MESH:C566386), cerebral venous thrombosis (MESH:D020767), hypercoagulable (MESH:D019851), thromboembolic (MESH:D013923), tachycardia (MESH:D013610), bleeding (MESH:D006470), nausea (MESH:D009325), autoimmune disease (MESH:D001327), infarction (MESH:D007238), miscarriage (MESH:D000022), Graves' disease (MESH:D006111), neurological deterioration (MESH:D009422), PE (MESH:D011655), fever (MESH:D005334), seizures (MESH:D012640), proptosis (MESH:D005094), neurological deficits (MESH:D009461)
- **Chemicals:** oxygen (MESH:D010100), thyroxine (MESH:D013974), FT3 (-), LMWH (MESH:D006495), methimazole (MESH:D008713), triiodothyronine (MESH:D014284)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G20210A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926680/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926680/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926680/full.md

---
Source: https://tomesphere.com/paper/PMC12926680